Cargando…

Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer

The Notch pathway is a well-established mediator of cell–cell communication that plays a critical role in stem cell survival, self-renewal, cell fate decisions, tumorigenesis, invasion, metastasis, and drug resistance in a variety of cancers. An interesting form of crosstalk exists between the Notch...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baker, Andrew T., Zlobin, Andrei, Osipo, Clodia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264417/ https://www.ncbi.nlm.nih.gov/pubmed/25566499 http://dx.doi.org/10.3389/fonc.2014.00360

Ejemplares similares

Gamma secretase inhibitors of Notch signaling
por: Olsauskas-Kuprys, Roma, et al.
Publicado: (2013)

Cancer stem cells and HER2 positive breast cancer: The story so far
por: Shah, Deep, et al.
Publicado: (2016)

Notch Signaling in Breast Cancer: A Role in Drug Resistance
por: BeLow, McKenna, et al.
Publicado: (2020)

Trastuzumab Resistance: Role for Notch Signaling
por: Mehta, Kinnari, et al.
Publicado: (2009)

NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications
por: Clementz, Anthony G, et al.
Publicado: (2011)

Notch versus the proteasome: what is the target of γ-secretase inhibitor-I?
por: Clementz, Anthony G, et al.
Publicado: (2009)

Targeting Breast Cancer Stem Cells Using Naturally Occurring Phytoestrogens
por: Nguyen, Mai, et al.
Publicado: (2022)

Crosstalk between PRLR and EGFR/HER2 Signaling Pathways in Breast Cancer
por: Kavarthapu, Raghuveer, et al.
Publicado: (2021)

The Effect of Cold Ischemia Time and/or Formalin Fixation on Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor-2 Results in Breast Carcinoma
por: Pekmezci, Melike, et al.
Publicado: (2012)

ATG9A loss confers resistance to trastuzumab via c-Cbl mediated Her2 degradation
por: Nunes, Joao, et al.
Publicado: (2016)

Metastatic Breast Cancer Coexisting With HER-2 Amplification and EGFR Exon 19 Deletion Benefits From EGFR-TKI Therapy: A Case Report
por: Jing, Wei, et al.
Publicado: (2020)

Crosstalk between PKCα and Notch-4 in endocrine-resistant breast cancer cells
por: Yun, J, et al.
Publicado: (2013)

Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification
por: Meedendorp, Arenda D., et al.
Publicado: (2018)

Immunotherapy for HER-2 positive breast cancer
por: Yang, Tingting, et al.
Publicado: (2023)

Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies
por: Bergado-Báez, Gretchen, et al.
Publicado: (2022)

DAXX-inducing phytoestrogens inhibit ER+ tumor initiating cells and delay tumor development
por: Peiffer, Daniel S., et al.
Publicado: (2020)

Moving Breast Cancer Therapy up a Notch
por: Mollen, Erik W. J., et al.
Publicado: (2018)

Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer
por: Xie, Yifan, et al.
Publicado: (2021)

A nomogram for predicting the HER2 status of circulating tumor cells and survival analysis in HER2-negative breast cancer
por: Yang, Yuqin, et al.
Publicado: (2022)

Metastatic HER2+ Breast Cancer: A Potentially Curable Disease?
por: Prior, Lisa, et al.
Publicado: (2017)

Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications
por: Godoy-Ortiz, Ana, et al.
Publicado: (2019)

New Advances in Targeted Therapy of HER2-Negative Breast Cancer
por: An, Junsha, et al.
Publicado: (2022)

Review of the status of neoadjuvant therapy in HER2-positive breast cancer
por: Dowling, Gavin P., et al.
Publicado: (2023)

The Role of Notch Signaling and Leptin-Notch Crosstalk in Pancreatic Cancer
por: Harbuzariu, Adriana, et al.
Publicado: (2018)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Notching on Cancer’s Door: Notch Signaling in Brain Tumors
por: Teodorczyk, Marcin, et al.
Publicado: (2015)

The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer
por: Wang, Chaokun, et al.
Publicado: (2021)

EGFR Expression in HER2-Driven Breast Cancer Cells
por: Weinberg, Florian, et al.
Publicado: (2020)

Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer After Dual-Target Neoadjuvant Therapy With Trastuzumab and Pertuzumab
por: Li, Fanfan, et al.
Publicado: (2022)

Breast Cancer With a HER2 IHC2+ and FISH HER2/CEP17 Ratio ≥2.0 and an Average HER2 Gene Copy Number <4.0 per Tumor Cell: HER2 mRNA Overexpression Is a Rare Event
por: Liu, Yuanyuan, et al.
Publicado: (2020)

The role of radiotherapy in HER2+ early-stage breast cancer patients after breast-conserving surgery
por: Yang, Huanzuo, et al.
Publicado: (2023)

Thyroid and renal cancers: A bidirectional association
por: Bellini, Maria Irene, et al.
Publicado: (2022)

Efficacy and Safety of Anti-HER2 Agents in Combination With Chemotherapy for Metastatic HER2-Positive Breast Cancer Patient: A Network Meta-Analysis
por: Zhang, Xiaohui, et al.
Publicado: (2021)

A Novel Small Molecular Antibody, HER2-Nanobody, Inhibits Tumor Proliferation in HER2-Positive Breast Cancer Cells In Vitro and In Vivo
por: Yan, Yan, et al.
Publicado: (2021)

The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy
por: Salemme, Vincenzo, et al.
Publicado: (2021)

Glycosylated Notch and Cancer
por: Pakkiriswami, Shanmugasundaram, et al.
Publicado: (2016)

The Prognosis of Single Hormone Receptor-Positive Breast Cancer Stratified by HER2 Status
por: Zhao, Hengqiang, et al.
Publicado: (2021)

The Link Between the Microbiota and HER2+ Breast Cancer: The New Challenge of Precision Medicine
por: Di Modica, Martina, et al.
Publicado: (2022)

Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases
por: Ma, Xiaoping, et al.
Publicado: (2022)

Remarkable Response of EGFR- and HER2-Amplified Metastatic Colon Cancer to Pyrotinib After Failed Multiline Treatments: A Case Report and Literature Review
por: Li, Hong-Shuai, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i03muhl4ula2ne74lu20gg5n4e